Select a community
Fibromyalgia And Chronic Fatigue Syndrome
Find out more about the PatientsLikeMe
Fibromyalgia And Chronic Fatigue Syndrome Community
Home > Community Treatment Reports > Levalbuterol Treatment Report
What is Levalbuterol?

Levalbuterol is in a class of medications called beta agonists. It works by relaxing and opening air passages to the lungs to make breathing easier. It is used to prevent or relieve the wheezing, difficulty breathing, and chest tightness caused by lung disease such as asthma and COPD.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell 		# of patients evaluated by
Asthma 6 1
COPD Chronic Obstructive Pulmonary Disease 1 0
Other 1 0

See all 12 patients currently taking Levalbuterol

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 100%
None
0 0%

Most commonly reported side effects

Cough with choking
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  0.31mg/3mL as needed 0.63mg/3mL as needed 1.25mg/3mL as needed 90mcg/inh as needed CFCfree45mcg/inh as needed 3 x 0.31 mg/3 mL daily 6 x 0.31 mg/3 mL daily 90 mcg daily
  1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 5 Number of Patients: 5 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Duration See details about how long patients take this treatment ▼

Currently Taking Levalbuterol

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
1 100%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 15, 2010.